KF
FOLD

Krilogy Financial’s Amicus Therapeutics FOLD Stock Holding History

Krilogy Financial’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-200
Closed -$3K – 784
2017
Q4 		$3K Hold
200
– – ﹤0.01% 649
2017
Q3 		$3K Buy
+200
New +$2.65K ﹤0.01% 699

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Krilogy Financial's FOLD Position: Q1 2018 in Review

Krilogy Financial sold out of Amicus Therapeutics (FOLD) in Q1 2018, closing a stake of 200 shares — an estimated $3K sold.

Krilogy Financial first reported a position in FOLD in Q3 2017 and held it in 2 quarters. The position peaked at $3K in Q4 2017. 203 funds tracked by Wall St. Rank hold FOLD as of Q1 2018.

  • Krilogy Financial reported no remaining Amicus Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Krilogy Financial sold 200 Amicus Therapeutics shares in Q1 2018, an estimated $3K.
  • Krilogy Financial first reported a position in Amicus Therapeutics in Q3 2017 and held it in 2 quarters.
  • Krilogy Financial's Amicus Therapeutics position peaked at $3K in Q4 2017.
  • 203 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2018.

Based on Krilogy Financial's 13F filing for Q1 2018, filed 15 May 2018.